Table 1.
Selected features of COVID-19 platform trials, as explicitly stated in registry pages, study documents, or trial websites as of July 13, 2020. If information was not available across these sources, it is designated as NA (“—”).⁎
| Trial registration ID | Trial phase | Platform designation | Adaptive features | Pre-specified decision rules | Bayesian methods | Available protocol | Available statistical analysis plan | Data sharing policy | Arms added | Arms dropped | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ACTT-1 | NCT04280705 | III | Yes | Sample size reassessment, graduation to control, futility stopping, efficacy stopping. | No | – | Yes | Yes | Public | – | – |
| REMAP-COVID (REMAP-CAP)⁎ | NCT02735707 | IV | Yes | Response-adaptive randomization, futility stopping, efficacy stopping, safety stopping, change in endpoint | Yes | Yes | Yes | Yes | By request | 9 | – |
| PRINCIPLE | – | III | Yes | Sample size reassessment, adaptive randomization, futility stopping, efficacy stopping, graduation to control | Yes | Yes | Yes | Yes | By request | – | – |
| CATCO | NCT04330690 | II | Yes | Change in primary endpoint, sample size reassessment | No | – | – | – | unclear | 3 | 2 |
| RECOVERY | NCT04381936 | II/III | Yes | Yes, unclear. | No | Yes, for pediatrics | Yes | Yes | By request | 10 | 8 |
| DisCoVeRy | NCT04315948 | III | Yes | Efficacy stopping, futility stopping, graduation to control | Yes | – | Yes | – | By request | 2 | 3 |
| NCT04328961 | NCT04328961 | II/III | Yes | Sample size reassessment | No | – | Yes | – | By request | – | – |
| ACOVACT | NCT04351724 | II/III | Potential | – | No | – | – | – | By request | 5 | 2 |
| NCT04354428 | NCT04354428 | II/III | Yes | Sample size reassessment, futility stopping, safety stopping, adaptive randomization | Yes | Yes | Yes | – | By request | 5 | 2 |
| COVID-Aging | NCT04359953 | III | Yes | – | No | – | – | – | – | – | – |
| CCAP | NCT04345289 | III | Yes | Futility stopping, graduation to control | No | – | – | – | – | – | 3 |
| COLHEART-19 | NCT04355143 | II | Potential | – | No | – | – | – | – | – | – |
| COVID19-HOPE | NCT04374903 | – | Yes | Yes, unclear | No | – | – | – | – | – | – |
| ACTT-2 | NCT04401579 | III | Yes | Futility stopping, efficacy stopping, safety stopping, sample size reassessment, graduation to control | No | – | Yes | – | Public | – | – |
| TACTIC-R | NCT04390464 | IV | Yes | Response adaptive randomization, futility stopping, efficacy stopping | Yes | Yes | Yes | – | – | – | – |
| BEAT COVID-19 | – | III | Yes | Response adaptive randomization | No | Yes | – | – | – | – | – |
| STARS | NCT04357730 | II | Yes | Efficacy stopping, safety stopping, futility stopping, adaptive enrichment, sample size reassessment | Yes | – | – | – | By request | – | – |
| Catalyst | – | II | Yes | Futility stopping, efficacy stopping | Yes | – | – | – | – | – | – |
| NCT04426695 | NCT04426695 | I/II/III | Potential | – | – | – | – | Public | 1 | – | |
| NCT04425629 | NCT04425629 | I/II/III | Yes | Futility stopping, efficacy stopping, population enrichment, sample size estimation, endpoint selection for III | No | Yes | Yes | – | Public/none | – | – |
| BLAZE-1 | NCT04427501 | II | Yes | Adaptive randomization, sample size reassessment, futility stopping | No | Yes | Yes | Yes | Public/none | 1 | – |
| FALCON-C19 | NCT04408170 | observational | Potential | Yes, unclear | No | – | – | – | – | – | – |
| DEFINE | NCT04473053 | II/III | Yes | Safety stopping | No | – | Yes | – | – | – | – |
| TACTIC-E | NCT04393246 | II/III | Yes | Futility stopping, safety stopping, efficacy stopping | Yes | Yes | Yes | – | – | – | – |
| TOGETHER 3 | – | – | Potential | Yes, unclear | No | – | – | – | Unclear | – | – |
| ASCOT (ADAPT) | NCT04483960 | III | Yes | Efficacy stopping, safety stopping, adaptive randomization | Yes | Planned as frequentist, has now moved to Bayesian | Yes | Yes | By request | 4 | 2 |
| COVERAGE | NCT04356495 | III | Yes | Futility stopping, efficacy stopping, safety stopping, graduation to control | Yes | – | Yes | – | By request | 2 | – |
| I-SPY_COVID | NCT04488081 | II | Potential | Futility stopping, efficacy stopping, graduation to control | No | Yes | – | – | By request | 6 | 4 |
| VIRCO | NCT04445467 | II | Yes | Yes, unclear | No | – | Yes | – | By request | – | – |
| ACTIV-3 | NCT04501978 | III | Yes | Efficacy stopping, futility stopping, safety stopping, graduation to control, sample size reassessment | Yes | – | Yes | – | By request | 3 | 1 |
| ACTIV-2 | NCT04518410 | II/III | Yes | Efficacy stopping, safety stopping | Yes | Yes | Yes | – | – | 9 | 3 |
| ACTIV-4 | NCT04505774 | IV | Yes | Efficacy stopping, futility stopping, safety stopping, graduation to control | Yes | Yes | Yes | – | Unclear | 2 | 1 |
| CROWN CORONA | NCT04333732 | III | Yes | Response adaptive randomization, futility stopping | No | Yes | – | – | By request | 1 | 3 |
| NCT04498273 | NCT04498273 | III | Potential | Yes, unclear | No | – | – | – | – | – | – |
| ALLIANCE | NCT04395768 | II | Yes | Sample size reassessment, efficacy stopping, futility stopping safety stopping | No | – | – | – | – | – | – |
| ANTICOV | – | III | Yes | Futility stopping, efficacy stopping, response adaptive randomization | Yes | Yes | Yes | – | Unclear | – | – |
| ACTIV-5 (BET-A) | NCT04583956 | II | Yes | Futility stopping, efficacy stopping | Yes | – | Yes | – | By request | – | – |
| ACTIV-1 IM | NCT04593940 | III | Yes | Futility stopping, efficacy stopping, safety stopping, sample size reassessment, graduation to control | Yes | – | Yes | – | – | – | – |
| ACTIV-5 (BET-B) | NCT04583969 | II | Yes | Futility stopping, efficacy stopping | Yes | – | Yes | – | By request | – | – |
| PROTECT-Surg | NCT04386070 | III | Yes | Futility stopping, efficacy stopping | No | Yes | – | – | – | – | – |
| AGILE-ACCORD | NCT04746183 | I/II | Yes | Futility stopping, efficacy stopping, sample size reassessment, change in primary endpoint | Yes | Yes | Yes | – | By request | 4 | – |
| ACCORD 2 | – | II | Yes | Futility stopping, sample size reassessment | No | – | Yes | – | Public | – | – |
| COVER | NCT04561063 | II | Yes | Yes, unclear | No | – | – | – | – | – | – |
| PROTECT | NCT04389359 | II/III | Yes | Sample size reassessment | No | Yes | – | – | – | – | – |
| COPPS | NCT04662086 | II | Potential | Yes, unclear. | – | – | – | – | – | – | |
| EU SolidAct | NCT04891133 | II/III | Yes | Graduation to control | No | – | Yes | – | Public | – | – |
| PROTECT-APT | NCT04844541 | Observational | Yes | – | No | – | – | – | – | – | – |
| NCT04650087 | NCT04650087 | III | Potential | – | No | – | – | – | – | – | – |
| ENFORCE | NCT04760132 | IV | Yes | – | No | – | – | – | – | – | – |
| COVERALL | NCT04805125 | III | Yes | – | No | – | – | – | – | – | – |
| NCT04889209 | NCT04889209 | I/II | Yes | Yes, unclear | No | – | – | – | – | – | – |
| ACCOMPLISH | NCT04829188 | Not Applicable | Potential | Adaptive randomization | No | – | – | – | – | – | – |
| OPTIMISE-C19 | NCT04790786 | III | Yes | Sample size reassessment | – | Yes | Yes | – | By request | – | – |
| ACTT-3 | NCT04492475 | III | Yes | Efficacy stopping, futility stopping, safety stopping, graduation to control, sample size reassessment | No | – | – | – | – | – | – |
| ACTIV-6 | NCT04885530 | III | Yes | Sample size reassessment, futility stopping, efficacy stopping | Yes | Yes | Yes | – | By request | – | – |
| TOGETHER 2 | NCT04403100 | III | Yes | Adaptive randomization, efficacy stopping, sample size re-assessment | No | Yes | Yes | – | By request | – | – |
| TOGETHER 1 | – | Unknown | Yes | – | – | – | – | – | – | – | – |
| ACTT-4 | NCT04640168 | III | Yes | Efficacy stopping, futility stopping, safety stopping, graduation to control, sample size reassessment | No | – | – | – | – | – | – |
⁎
REMAP-CAP consists of many treatment domains.